OMERS ADMINISTRATION Corp Reduces Stock Position in Becton, Dickinson and Company $BDX

Key Points

• OMERS ADMINISTRATION Corp reduced its stake in Becton, Dickinson and Company by 14.2%, selling 1,712 shares and holding 10,373 shares valued at $2,376,000.
• Several institutional investors, including GQG Partners LLC, Vanguard Group, and Massachusetts Financial Services Co., have increased or established stakes in Becton, Dickinson and Company during the first quarter, with institutional holdings now at 86.97%.
• Becton, Dickinson and Company reported earnings of $3.68 EPS for the latest quarter, exceeding estimates and showing a revenue increase of 10.4% year-over-year.

OMERS ADMINISTRATION Corp lowered its position in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) by 14.2% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 10,373 shares of the medical instruments supplier's stock after selling 1,712 shares during the period. OMERS ADMINISTRATION Corp's holdings in Becton, Dickinson and Company were worth $2,376,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Smallwood Wealth Investment Management LLC acquired a new stake in shares of Becton, Dickinson and Company during the first quarter valued at about $27,000. REAP Financial Group LLC boosted its holdings in Becton, Dickinson and Company by 75.3% in the fourth quarter. REAP Financial Group LLC now owns 128 shares of the medical instruments supplier's stock valued at $29,000 after purchasing an additional 55 shares during the period. Alpine Bank Wealth Management acquired a new position in Becton, Dickinson and Company during the 1st quarter worth $29,000. Cornerstone Planning Group LLC increased its holdings in Becton, Dickinson and Company by 341.4% during the 1st quarter. Cornerstone Planning Group LLC now owns 128 shares of the medical instruments supplier's stock worth $29,000 after purchasing an additional 99 shares during the period. Finally, Kelly Lawrence W & Associates Inc. CA acquired a new stake in Becton, Dickinson and Company in the 1st quarter valued at about $31,000. Institutional investors and hedge funds own 86.97% of the company's stock.

Insider Buying and Selling

In other news, EVP Michael David Garrison sold 1,185 shares of the firm's stock in a transaction on Friday, July 18th. The stock was sold at an average price of $180.29, for a total value of $213,643.65. Following the completion of the transaction, the executive vice president owned 4,887 shares in the company, valued at $881,077.23. This trade represents a 19.52% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Claire Fraser sold 863 shares of Becton, Dickinson and Company stock in a transaction dated Friday, August 8th. The stock was sold at an average price of $192.30, for a total transaction of $165,954.90. Following the transaction, the director owned 23,143 shares of the company's stock, valued at approximately $4,450,398.90. The trade was a 3.59% decrease in their position. The disclosure for this sale can be found here. 0.36% of the stock is currently owned by company insiders.

Becton, Dickinson and Company Stock Performance

NYSE:BDX traded down $4.88 during mid-day trading on Tuesday, reaching $188.11. The stock had a trading volume of 1,630,275 shares, compared to its average volume of 2,612,290. Becton, Dickinson and Company has a twelve month low of $163.33 and a twelve month high of $251.99. The business has a 50 day simple moving average of $183.53 and a 200 day simple moving average of $193.61. The firm has a market capitalization of $53.92 billion, a price-to-earnings ratio of 33.83, a PEG ratio of 1.44 and a beta of 0.27. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.62 and a current ratio of 1.10.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last issued its earnings results on Thursday, August 7th. The medical instruments supplier reported $3.68 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.40 by $0.28. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%.The business had revenue of $5.51 billion during the quarter, compared to the consensus estimate of $5.50 billion. During the same period in the prior year, the business posted $3.50 EPS. The company's revenue for the quarter was up 10.4% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. On average, analysts expect that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 30th. Shareholders of record on Monday, September 8th will be issued a $1.04 dividend. The ex-dividend date of this dividend is Monday, September 8th. This represents a $4.16 dividend on an annualized basis and a yield of 2.2%. Becton, Dickinson and Company's dividend payout ratio (DPR) is 74.82%.

Analyst Ratings Changes

Several equities analysts recently commented on BDX shares. Citigroup lowered Becton, Dickinson and Company from a "strong-buy" rating to a "hold" rating and dropped their target price for the company from $217.00 to $185.00 in a report on Thursday, May 22nd. Wells Fargo & Company boosted their price target on shares of Becton, Dickinson and Company from $172.00 to $184.00 and gave the company an "equal weight" rating in a research report on Friday, August 8th. Wall Street Zen upgraded Becton, Dickinson and Company from a "hold" rating to a "buy" rating in a research note on Saturday, August 9th. Morgan Stanley increased their price objective on Becton, Dickinson and Company from $196.00 to $197.00 and gave the company an "overweight" rating in a report on Monday, August 11th. Finally, Piper Sandler reaffirmed a "neutral" rating and issued a $200.00 target price (up from $185.00) on shares of Becton, Dickinson and Company in a report on Friday, August 8th. Four equities research analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the stock. According to data from MarketBeat, Becton, Dickinson and Company has an average rating of "Hold" and an average target price of $211.44.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.